CORE Biomedicine raised $21 million Series A to advance novel cancer therapeutics and received an AMED grant to support research and development.
- Amount
- $21M
- Stage
- Series A
- Announced
- 28 July 2026
- Leads
- UTokyo Innovation Platform Co., Ltd., Elikon Venture
- Other investors
- InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., Root Venture Partners
- Use of funds
- Accelerate development of novel lineage-based oncology therapies and advance the precision oncology pipeline toward early clinical development.
- Checked
- Amount and date checked against the press source